within Pharmacolibrary.Drugs.ATC.M;

model M01AA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.006666666666666667,
    adminDuration  = 600,
    adminMass      = 0.4,
    adminCount     = 1,
    Vd             = 0.0087,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Oxyphenbutazone is a nonsteroidal anti-inflammatory drug (NSAID) of the pyrazolidinedione class, formerly used in the treatment of rheumatoid arthritis and other inflammatory conditions. Due to safety concerns, particularly risk of severe adverse hematological reactions such as agranulocytosis, the drug is no longer approved or widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported for healthy adult volunteers (sex not specified) following oral administration.</p><h4>References</h4><ol><li>J Aarbakke,Clinical pharmacokinetics of phenylbutazone.,Clinical pharmacokinetics,1978<a href='https://pubmed.ncbi.nlm.nih.gov/359213/'>https://pubmed.ncbi.nlm.nih.gov/359213/</a></li><li>N S Matthews, K E Peck, T S Taylor, K L Mealey,Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys.,American journal of veterinary research,2001<a href='https://pubmed.ncbi.nlm.nih.gov/11341383/'>https://pubmed.ncbi.nlm.nih.gov/11341383/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M01AA03;
